Zestril drug class
Pro Research Analysisby 
Searched over 200M research papers
Zestril Drug Class: ACE Inhibitors
Introduction to ACE Inhibitors
Angiotensin-converting enzyme (ACE) inhibitors are a class of medications primarily used to treat hypertension (high blood pressure) and congestive heart failure. These drugs work by inhibiting the enzyme responsible for converting angiotensin I to angiotensin II, a potent vasoconstrictor that increases blood pressure. By blocking this conversion, ACE inhibitors help to relax blood vessels, thereby lowering blood pressure and reducing the workload on the heart.
Zestril: A Carboxylalkyl ACE Inhibitor
Zestril, also known by its generic name lisinopril, is a carboxylalkyl derivative and a well-known ACE inhibitor. It is widely used for managing hypertension and heart failure. Lisinopril is effective in reducing blood pressure and improving heart function by preventing the formation of angiotensin II, which in turn helps to relax blood vessels and decrease blood volume.
Bioequivalence Studies of Zestril
Bioequivalence studies are essential to ensure that different brands of the same medication provide the same therapeutic effect. A study comparing Zestril (AstraZeneca, UK) and Lisotec (Julphar, UAE) demonstrated that both brands are bioequivalent. This means that they have similar pharmacokinetic profiles, including parameters like AUC (Area Under the Curve), CMAX (maximum concentration), and TMAX (time to reach maximum concentration). The study involved 28 healthy volunteers and concluded that there were no significant differences between the two formulations, confirming that Lisotec is bioequivalent to Zestril.
In Vitro Analysis of Zestril
In vitro studies further support the efficacy and quality of Zestril. A comparative analysis of 5 mg tablets of Lizinocor (a lisinopril-containing drug produced by GMP, Georgia) and Zestril showed that both medications have high-quality outlet characteristics. The average percent quantity outlet for Lizinocor was 97.65%, while Zestril was 95.88%, indicating that both formulations meet the required standards for drug release and effectiveness.
Conclusion
Zestril, a carboxylalkyl ACE inhibitor, is a reliable medication for treating hypertension and heart failure. Bioequivalence studies confirm that Zestril and its generic counterparts, such as Lisotec, provide similar therapeutic effects. In vitro analyses further validate the high quality and efficacy of Zestril, making it a trusted choice in the management of cardiovascular conditions.
Sources and full results
Most relevant research papers on this topic